利伐沙班相关超敏反应性皮疹一例报告
本文报告一例69岁白人女性癌症相关深静脉血栓合并肺栓塞患者,在由依诺肝素皮下注射转为口服利伐沙班约48小时后出现弥漫性斑丘疹,停药并予地塞米松后皮疹明显消退,Naranjo量表评估提示利伐沙班为 probable 原因。
要点
- 利伐沙班用药后约48小时可出现弥漫性斑丘疹,停药后需换用其他抗凝药。
- Naranjo量表评估提示利伐沙班为 probable 原因。
- 换回依诺肝素并加用地塞米松后皮疹明显消退。
核心结论
- 一例69岁白人女性在利伐沙班治疗第3天出现弥漫性斑丘疹,停药并予地塞米松后症状缓解。
研究设计与样本
- 单例病例报告,患者为69岁白人女性,因癌症相关深静脉血栓合并肺栓塞接受抗凝治疗。
主要发现
- 患者由依诺肝素皮下注射转为口服利伐沙班约48小时后,颈部及躯干出现弥漫性斑丘疹并蔓延至四肢。
- 口服苯海拉明25-50 mg每6-8小时未能缓解症状。
- 停用利伐沙班并换回依诺肝素1 mg/kg每12小时皮下注射,加用口服地塞米松4 mg每日两次,第8天皮疹明显消退仅存于大腿。
- Naranjo量表评估提示利伐沙班为超敏反应 probable 原因。
- 既往有4例利伐沙班超敏反应表现为皮疹的病例报告,本例为首例女性及首例活动性癌症背景下治疗DVT和PE的患者。
临床怎么用
- 使用利伐沙班期间出现弥漫性皮疹应警惕超敏反应,及时评估并考虑停药。
- 疑似利伐沙班超敏反应时可换用依诺肝素等替代抗凝药,必要时加用糖皮质激素。
局限性
- 为单例病例报告,因果关系评估基于Naranjo量表,不能确立普遍性结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: A case of a patient who developed a hypersensitivity reaction to rivaroxaban in the form of a diffuse, exanthematous rash is reported. SUMMARY: After starting rivaroxaban for treatment of cancer-associated deep vein thrombosis (DVT) with pulmonary embolism (PE), a 69-year-old Caucasian woman arrived at an oncology clinic with a diffuse, exanthematous (morbilliform) rash on her neck and torso, spreading to her upper and lower extremities. She reported that the symptoms started to develop about 48 hours after transitioning from subcutaneous enoxaparin to oral rivaroxaban. The patient's symptoms did not subside with diphenhydramine 25-50 mg orally every 6-8 hours. The patient was switched back to enoxaparin therapy for continued anticoagulation therapy. On day 5, rivaroxaban and diphenhydramine were discontinued. Oral dexamethasone 4 mg twice daily was initiated, and the patient transitioned from rivaroxaban to enoxaparin 1 mg/kg every 12 hours subcutaneously. On day 8, the rash had diminished considerably and was present only on her thighs. Analysis of the case using the adverse drug reaction probability scale of Naranjo et al. indicated that rivaroxaban was the probable cause of the hypersensitivity reaction. Four prior case reports of rivaroxaban hypersensitivity manifesting as a rash have been previously reported, with this being the first in a female and the first in a patient undergoing treatment of DVT and PE in the setting of active cancer. CONCLUSION: A 69-year-old Caucasian woman developed a diffuse, exanthematous rash on day 3 of rivaroxaban treatment. Symptoms abated after rivaroxaban discontinuation and treatment with dexamethasone.
引用
- Rudd KM, Panneerselvam N, Patel A, et al. Rash associated with rivaroxaban use. Am J Health Syst Pharm. 2018. PMID: 29348123. doi:10.2146/ajhp160985
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。